Roche’s Tecentriq gets fourth European lung cancer indicationRoche’s cancer immunotherapy Tecentriq has been granted a new use by European regulators, for the first-line treatment of Share XRoche’s Tecentriq gets fourth European lung cancer indicationhttps://pharmaphorum.com/news/roches-tecentriq-gets-fourth-european-lung-cancer-indication/
Novo Nordisk ups forecasts after Q1 profit boostAfter an indifferent period Novo Nordisk has kicked off 2021 on the front foot, raising its financial forecast Share XNovo Nordisk ups forecasts after Q1 profit boosthttps://pharmaphorum.com/news/novo-nordisk-ups-forecasts-after-q1-profit-boost/
MDMA on track for 2023 approval as PTSD therapy, says developerA medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp Share XMDMA on track for 2023 approval as PTSD therapy, says developerhttps://pharmaphorum.com/news/mdma-on-track-for-2023-approval-as-ptsd-therapy-says-developer/
FDA extends tie-up with CN Bio to test ‘lung-on-a-chip’ techThe FDA has extended a collaboration with the UK firm CN Bio to investigate a “lung-on-a-chip” model to Share XFDA extends tie-up with CN Bio to test ‘lung-on-a-chip’ techhttps://pharmaphorum.com/news/fda-extends-tie-up-with-cn-bio-to-test-lung-on-a-chip-tech/
Pfizer says COVID-19 jab could rake in $26bn this yearPfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it Share XPfizer says COVID-19 jab could rake in $26bn this yearhttps://pharmaphorum.com/news/pfizer-says-covid-19-jab-could-rake-in-26bn-this-year/
EU starts rolling review of Sinovac’s COVID-19 vaccineEurope’s regulator has begun a rolling review of Sinovac’s COVID-19 vaccine, known as Vero Cell. The vaccine is Share XEU starts rolling review of Sinovac’s COVID-19 vaccinehttps://pharmaphorum.com/news/eu-regulator-begins-review-of-sinovacs-covid-19-vaccine/
Vicore signs deal with Alex to develop digital therapeutic to support IPF patientsRare disease specialist Vicore Pharma has signed an agreement with Alex Therapeutics to test a digital therapeutic designed Share XVicore signs deal with Alex to develop digital therapeutic to support IPF patientshttps://pharmaphorum.com/news/vicore-signs-deal-with-alex-to-develop-digital-therapeutic-to-support-ipf-patients/
MoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimabThere’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a Share XMoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimabhttps://pharmaphorum.com/news/moonlake-launches-licensing-in-merck-kgaas-cosentyx-challenger-sonelokimab/
AstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAAstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to Share XAstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDAhttps://pharmaphorum.com/news/astrazenecas-farxiga-gets-first-kidney-disease-ok-from-fda/
